TARA-002 demonstrates 72% complete response rate at any time in BCG-Naïve patientsTARA-002 demonstrates a 69% complete response rate at the 6-month landmark and a 50% complete response rate at the 12-month landmark in BCG-Naïve patientsFavorable safety and tolerability profile observed with no Grade 3 or greater treatment-related adverse events reportedCompany obtained written feedback from FDA on registrational path forward for TARA-002 in BCG-Naïve patientsCompany remains on track to report interim result ...

Core Insights - Jupiter Neurosciences is advancing its JOTROL platform into a Phase 2a clinical trial for Parkinson's disease, marking a significant regulatory milestone with FDA clearance [4][5] - The company launched its Nugevia consumer brand, targeting the $8 trillion longevity market, with initial products designed to enhance brand visibility and generate revenue [6][7] - Jupiter has secured strategic financing of up to $20 million to support its clinical and commercial initiatives, providing flexibility and control over capital access [10][11][12] Company Achievements - Jupiter Neurosciences completed its first full year as a public company, establishing a foundation for long-term value creation and executing major initiatives [2][3] - The JOTROL platform has demonstrated a nine-fold improvement in bioavailability and effective blood-brain barrier penetration, supporting its therapeutic potential [5][20] - The Nugevia product line includes three initial offerings—GLO, PWR, and MND—integrating JOTROL with other bioavailable ingredients to support various aspects of health [7][21] Market Positioning - The Nugevia brand is supported by high-profile ambassadors, enhancing its market presence and performance-driven identity [8] - A dedicated website for Nugevia was launched, facilitating pre-orders and establishing a subscription-based model for recurring revenue [9] - Jupiter's dual-path strategy focuses on both therapeutic applications for CNS disorders and consumer longevity products, positioning the company for growth in both sectors [17][22] Financial Strategy - The strategic financing agreement with Yorkville Advisors allows Jupiter to access capital as needed, ensuring stability during its growth phase [10][11] - The financing structure is designed to be non-toxic and fully controlled by the company, allowing for advantageous capital access [11][12] - The company aims to strengthen its financial position while supporting ongoing operations and clinical trials without compromising shareholder interests [12]

EL MONTE, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- GigaCloud Technology Inc (Nasdaq: GCT) (“GigaCloud” or the “Company”), a pioneer of global end-to-end B2B technology solutions for large parcel merchandise, today announced that Erica Wei, its Chief Financial Officer, and Iman Schrock, its President, will conduct one-on-one meetings with investors at the 14th Annual ROTH Deer Valley Event, being held from December 10 through December 13 in Park City, Utah. To schedule a meeting, please contact your ROTH re ...

STAMFORD, Conn., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Star Group, L.P. (the “Company” or “Star”) (NYSE: SGU), a leading home energy distributor and services provider, today announced that it will release its fiscal 2025 fourth quarter results after the close of trading on December 8, 2025. Members of Star's management team will host a webcast and conference call at 11:00 a.m. Eastern Time the following day, December 9, 2025, to review the three and twelve months ended September 30, 2025. The webcast will be ac ...

FDA feedback provides clear framework for Nexalin’s planned U.S. Pilot Study and supports a potential De Novo pathway for the Gen-2 SYNC™ device in Alzheimer’s diseaseHOUSTON, TX, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the successful completion of a substantive Q-Submission (“Q-Sub”) meeting with the U.S. Food and Drug Administration (“FDA”) regarding it ...

VANCOUVER, British Columbia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- SAGA Metals Corp. ("SAGA" or the "Company") (TSXV: SAGA) (OTCQB: SAGMF) (FSE: 20H), a North American exploration company advancing critical mineral discoveries, is pleased to announce the successful completion of the first phase of drilling in the Trapper Zone’s northern section (“Trapper North”) including four drill holes over 1,073 m and has initiated phase 2 in the south (“Trapper South”) including two drill holes over 445 m completed to date ...

TORONTO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- NowVertical Group Inc. (TSXV: NOW) (“NOW” or the “Company”), a leading data and AI solutions provider, is pleased to announce its participation in an upcoming investor webinar hosted by Bristol Capital Ltd. Webinar: Overview of NowVertical’s Business Date: December 10, 2025Time: 2pm ESTOverview: The webinar will cover key areas of the Company’s business including strategic direction, latest business developments, and growth strategy. Attendees will also have the o ...

LAS VEGAS, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Asia Broadband Inc. (OTC: AABB) (“AABB” or the “Company”) is pleased to announce that the Company has developed a silver-backed token AABBS and is preparing the launch and minting processes of the new cryptocurrency. Planning is underway to mint AABBS in close proximity to the upcoming release of the next generation AABB Wallet. The Company’s continued increases in quarterly silver production, along with numerous silver market price growth fundamentals, led to ma ...

FORT MILL, S.C., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a leading U.S.-based medical device company focusing on advanced solutions in the cardiac electrophysiology market, is proud to announce that its VIVO™ system has successfully secured a significant tender at Albert Szent-Györgyi Health Centre (Szeged University Hospital) in Hungary. This achievement marks Catheter Precision’s inaugural installation in Hungary and reinforces its commitment to growth across Cen ...

Humana and UnitedHealthcare, which granted authorization in November, are the two largest Medicare Advantage providers in the U.S., accounting for 47% of all Medicare Advantage enrollees This latest approval will help enhance timely access to cutting-edge personal exoskeleton solutions for individuals with spinal cord injury Reimbursement coverage is expected to give Lifeward stronger revenue and cash flow dynamics to scale growth MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) ...